IMR Press / JIN / Special Issues / Tau_Alzheimer

Molecular Insights into Tau Pathology in Alzheimer's Disease (AD) and Related Therapeutic Strategies 

Submission deadline: 30 March 2024
Special Issue Editor
  • Ashok Iyaswamy, PhD
    School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China
    Interests: neurodegenerative diseases; autophagy; biomaterials; drug delivery; ROS & oxidative stress
Special Issue Information

Dear Colleagues,

Alzheimer’s disease (AD) is an age-associated neurodegenerative disease (ND) that impairs memory and cognition, as well as affecting behavioral and social activities. AD is the most common brain disease in humans, with a prevalence of 4-8% in the elderly population worldwide. The global AD population is estimated to increase to 114 million by 2050. Deficiency of the autophagy-lysosomal pathway (ALP) has been shown to play a key role in the pathogenesis of neurodegenerative disorders such as AD, which then manifests as memory loss. Despite a plethora of laboratory and clinical research, there is still no effective treatment for AD. Therefore, considerable challenges remain for researchers in the scientific community and for medical experts to better understand the disease pathogenesis of AD and to develop effective therapeutics. Over the past decades, drug discovery based on the reduction of Aβ plaques has not shown good clinical efficacy. In contrast, the targeting of neurofibrillary tangles (NFTs) appears more likely to be successful. This is because NFTs are comprised of hyperphosphorylated, aggregated and misfolded Tau protein that correlate with cognitive impairment. The development of drugs to prevent the formation of aberrant Tau or to enhance its clearance could therefore be a promising strategy for AD treatment. The promotion of cellular autophagy and ALP using novel phytochemicals from herbal medicines may be an effective AD therapy. One of the most recent and promising strategies for drug discovery in AD is to use traditional herbal medicines to modulate memory improvement and tau degradation. 

This Research Topic welcomes contributions in the form of original research articles, reviews and opinions that address/summarize our understanding of Amyloid β and Tau aggregates in the pathogenesis, prognosis, and therapeutics of AD and the challenges remaining.

Dr. Ashok Iyaswamy
Guest Editor

Alzheimer’s disease
autophagy-lysosomal pathway
small molecules
Tau pathology
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.

Back to top